E-LIB Suche - Ergebnisse für: Camarda, F.

1

60P Exploration of homologous recombination deficiency test..:

Camarda, F. ; Marino, I. ; Giacomini, F....
ESMO Open. 9 (2024) - p. 103567 , 2024

Link: https://doi.org/10.1016/..

2

42MO Interpreting somatic POLE mutations in endometrial can..:

Trozzi, R. ; De Marco, L. ; Mastrantoni, L....
ESMO Open. 9 (2024) - p. 103590 , 2024

Link: https://doi.org/10.1016/..

3

Chemotherapy Rechallenge or Reintroduction compared to Rego..:

Calegari, MA ; Zurlo, IV ; Dell'Aquila, E...
Clinical Colorectal Cancer. , 2024

Link: https://doi.org/10.1016/..

4

5P Ovarian cancer ESCAT gene actionability: Cinderella wear..:

Camarda, F. ; Mastrantoni, L. ; Nero, C....
ESMO Open. 9 (2024) - p. 103505 , 2024

Link: https://doi.org/10.1016/..

5

102P A retrospective description of actionable mutations in..:

Camarda, F. ; Nero, C. ; Giacomini, F....
ESMO Open. 9 (2024) - p. 102328 , 2024

Link: https://doi.org/10.1016/..

6

96P Analysis of concordance between microsatellite instabil..:

Duranti, S. ; Camarda, F. ; Nero, C....
ESMO Open. 8 (2023) 1 - p. 101906 , 2023

Link: https://doi.org/10.1016/..

7

10P An adapted CGP-based model to interpret POLE mutations ..:

Trozzi, R. ; Ottaviani, M. ; Nero, C....
ESMO Open. 8 (2023) 1 - p. 101656 , 2023

Link: https://doi.org/10.1016/..

8

Combining PARP inhibition and immune checkpoint blockade in..:

Musacchio, L. ; Cicala, C.M. ; Camarda, F....
ESMO Open. 7 (2022) 4 - p. 100536 , 2022

Link: https://doi.org/10.1016/..

9

A phase 2 study of temozolomide in pretreated metastatic co..:

Calegari, M A ; Inno, A ; Monterisi, S...
British Journal of Cancer. 116 (2017) 10 - p. 1279-1286 , 2017

Link: https://doi.org/10.1038/..

10

Therapeutic Potential of Tisotumab Vedotin in the Treatment..:

Agostinelli V ; Musacchio L ; Camarda F...
https://www.dovepress.com/therapeutic-potential-of-tisotumab-vedotin-in-the-treatment-of-recurre-peer-reviewed-fulltext-article-CMAR. , 2023

Link: https://doaj.org/article..

11

Combining PARP inhibition and immune checkpoint blockade in..:

Musacchio, L ; Cicala, C.M ; Camarda, F...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294238/. , 2022

Link: http://www.ncbi.nlm.nih...

12

Persistence of C-reactive protein increased levels and high..:

Navarini L ; Currado D ; Marino A...
info:eu-repo/semantics/altIdentifier/pmid/35525861. , 2022

Link: https://hdl.handle.net/1..

13

Evaluation of second-line anti-VEGF after first-line anti-E..:

Parisi A ; Cortellini A ; Cannita K...
info:eu-repo/semantics/altIdentifier/pmid/32429380. , 2020

Link: http://hdl.handle.net/11..

14

Evaluation of second-line anti-VEGF after first-line anti-E..:

Parisi A ; Cortellini A ; Cannita K...
info:eu-repo/semantics/altIdentifier/pmid/32429380. , 2020

Link: http://hdl.handle.net/11..

15

A phase 2 study of temozolomide in pretreated metastatic co..:

Calegari M. A ; Orlandi A ; Cassano A...
info:eu-repo/semantics/altIdentifier/pmid/28427088. , 2017

Link: http://hdl.handle.net/10..